Abstract Ischemic strokes, intracranial hemorrhages (ICH) and deep venous thromboembolism (DVT) are clinically important events in patients with gliomas. In this multicentre, noninterventional observational study, current data pertaining to frequency, contributing factors and outcomes of vascular events during times of anti-angiogenic therapy with the antibody against vascular endothelial growth factor, bevacizumab (BEV) was collected from the German Glioma Network. Among 3,889 glioma patients, 70 ischemic strokes (1.8 %) and 123 ICH (3.2 %) were recorded. 143 DVT (5.0 %) were recorded in 2,855 patients. Rates of DVT and ICH, but not of ischemic strokes, increased with the World Health Organization (WHO) grade of glioma. In 81 BEV-treated patients, five ischemic strokes (6.2 %), one ICH (1.2 %) and six DVT (7.4 %) were documented. Compared to patients that were not treated with BEV, ischemic stroke rate was significantly higher during treatment with BEV (p \ 0.001). The rates of DVT (p = 0.123) or ICH (p = 0.571) in BEVtreated patients did not differ. On cerebral magnetic resonance imaging (MRI), BEV-related ischemic strokes appeared as diffusion-restricted sites next to contrastenhancing tumor. 67 % of ICH, 61 % of ischemic strokes and 18 % of DVT occurred postoperatively (within Neurol (2013) 260:847-855 DOI 10.1007 30 days after tumor resection). Outcome after postoperative ICH was significantly worse than after spontaneous ICH (p = 0.008). Ischemic stroke outcomes did not differ between postoperative and spontaneous occurrence (p = 0.401). Rate of pulmonary embolism did not differ significantly between postoperative and spontaneous DVT (p = 0.133). Relatively low rates of ICH and DVT might be partially due to a high proportion of low-grade gliomas in this patient cohort. The finding of a relevant number of symptomatic, therapy-associated intracerebral diffusion restrictions should be controlled in ongoing phase III studies.
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Introduction
Ischemic strokes, intracranial hemorrhages (ICH) and deep venous thromboembolism (DVT) are frequent in patients with glioma [13, [22] [23] [24] .
Consequences may be severe, and result in deteriorating quality of life and increasing disability. It is assumed that ICH and ischemic strokes [13] are particularly associated with a dismal prognosis. Current data pertaining to frequency, causes and outcomes of vascular events appear crucial for treating physicians, particularly during times of anti-angiogenic therapies and their possible side effects.
The primary objective of this multicentre, noninterventional observational study was a comprehensive analysis of spontaneous and post-surgical vascular complications in glioma patients, with a special focus on the effect of antiangiogenic therapy with the antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV).
Methods

Data collection
Clinical data pertaining to ischemic strokes, ICH and DVT in glioma patients (n = 3,889) have been collected in the German Glioma Network (GGN). The GGN is a multicentric (Bochum, Bonn, Düsseldorf, Dresden, Freiburg, Hamburg, Heidelberg, München, Tübingen) prospective cohort study that enrolled newly diagnosed patients with various types of glioma and frozen tissue asservation from October 2004 to 2010. In addition to the clinical centres, there are several reference centres for collection and analysis of clinical, pathological and molecular parameters of glioma. The patients were not commonly enrolled into clinical trials, and treatment decisions were made by the treating physicians, patients and their families, without awareness of results of molecular parameters. Progression was defined locally according to Macdonald criteria, and not centrally reviewed. All patients gave written informed consent. All activities of the GGN have been approved by the review boards of the participating institutions. Within the GGN, patients are prospectively followed by standardized clinical and magnetic resonance imaging (MRI) examinations. Data are documented on CRF and centrally stored and monitored as outlined before (http://www.gliomnetzwerk.de) [28] . The GGN did not intend interventions. The GGN established an observational cohort with standard operating procedures for follow-up and data acquisition at all levels.
Between October 2004 and January 2010, data for 3,889 patients were recorded in a central database. The clinical centres centrally recorded vascular complications. In addition to the basic event data (type and date of event), the individual centres recorded numerous other patient data (age, glioma type, date of resection, adjuvant therapies, event-related death) on dedicated case record forms for central data storage. For completion and amendment of centrally documented data, additional chart information (clinical outcome, concomitant medication, vascular risk factors) were collected from the centres in 2010 by CÁS..
Determination of event rate
From 3,889 patients included between 2004 and 2010 in the GGN, rates of ischemic strokes and ICH were determined. The DVT rate was calculated from 2,855 patients, since two clinical centres did not document DVT. Occurrence within 30 days after surgery was classified as postoperative.
Additionally, event rates were calculated for the most frequent glioma types.
Determination of event rate under BEV treatment and characterisation of events Within the GGN patient population, 81 patients were treated with BEV. Events were regarded as BEV-related when they happened during or max. 4 weeks after BEV therapy.
The number of events within 81 patients that were treated with BEV was compared with the number of nonpostoperative events among 3,808 patients that had never been treated with BEV. Detailed clinical information and MRI images from BEV-related ischemic strokes were collected from the clinical centres.
Comparison of postoperative and non-postoperative events All vascular complications were analysed separately, according to postoperative or non-postoperative occurrence.
For ischemic strokes, the following characteristics were looked at and compared between the two groups: patient age, tumor histology, clinical outcome, cerebrovascular risk factors (arterial hypertension, diabetes mellitus, atrial fibrillation, persisting foramen ovale) and associated therapy. Clinical outcome was determined from clinical data by retrospective estimation of modified rankin score (MRS) after the event. This approach has been used before [13] , and gives an approximation of severity of stroke. It does not take into account the MRS before stroke.
For Table 2 ).
The ischemic stroke rate did not differ between tumor entities (p = 0.383), whereas ICH rates increased significantly with degree of malignancy (p \ 0.001). Similarly, there was a significant correlation between WHO grade and the frequency of DVT ( Table 2 , p \ 0.001). Interestingly, in case of non-postoperative events, this correlation between the WHO grade and frequency of vascular events was only seen for DVT (p \ 0.001, data not shown).
Rate and characterization of BEV-associated vascular events
During or maximal 4 weeks after BEV therapy, six DVT (7.4 %), one ICH (1.2 %) and five ischemic strokes (6.2 %) in the group of BEV-treated patients (n = 81) were documented (Table 3) . One patient suffered from two ischemic events within 8 weeks.
Among the patients that were never treated with BEV (n = 3,801), 100 DVT (3.6 %), 39 ICH (1.0 %) and 22 ischemic strokes (0.6 %) were registered as non-postoperative events.
In comparison, ICH rates were similar (1.2 % vs. 1.0 %, p = 0.571). The rate of DVT showed a trend for higher frequency under BEV (7.2 % vs. 3.6 %, p = 0.123). Ischemic strokes were more frequent during treatment with BEV (6.2 % vs. 0.6 %, p \ 0.001).
As these data indicate a higher frequency of ischemic strokes in patients treated with BEV compared with patients never treated with this drug, more detailed clinical data and MRI images were analyzed from the four affected patients.
All ischemic strokes were situated on the side of the tumor, either in deep white matter, basal ganglia or thalamus, and all patients had been treated with radiotherapy during the course of disease. Median patient age was 63 (59-69), median MRS after the event was 3 (3-6). One patient died shortly after the event. Two of four patients showed vascular risk factors. In all patients, partial response to BEV was diagnosed.
In the analysis of the 3/5 available MRI scans, lacunary rather than territory diffusion-restricted areas in proximity to residual contrast enhancement were visible (Table 4 ; Fig. 1 ).
Comparisons between postoperative and nonpostoperative events in the GGN patient population
Ischemic strokes
43/70 (61 %) ischemic strokes occurred postoperatively and 27/70 (39 %) without relation to surgery (Table 5) . Patient age was lower in the group of patients with postoperative events than in the group with non-postoperative events (53 years vs. 61 years, p = 0.098). Tumor entities were distributed without difference (p = 0.582). The rate of severe disability did not differ between postoperative and non-postoperative brain infarctions (MRS [ 3: 71 % vs. 59 %, p = 0.401). Patients with postoperative brain infarctions showed a significantly lower rate of cerebrovascular risk factors (38 % with at least one risk factor) than patients with non-postoperative events (73 % with at least one risk factor, p = 0.014). In 14 of 27 (52 %) patients with non-postoperative ischemic strokes, radiotherapy to the involved part of the brain was part of the treatment a median of 1.5 years before the event. In all 
Intracranial hemorrhages
Of all ICH, 68 % (83/123) intracranial hemorrhages occurred within 7 days after tumor resection, whereas 32 % (40/123) occurred without close timely relation to surgery ( Table 6) 
Deep venous thromboembolism
DVT occurred in 23/130 (18 %) of the events within 7 days after tumor resection, and in 50/130 (38 %) within 4 weeks after tumor surgery (Table 7) .
In the group of non-postoperative DVT, patients were of older median age (59 years vs. 51 years, p = 0.018). Glioma types were distributed without difference in the two groups (p = 0.623). Median steroid dose was not different between the two groups (median 1 mg vs. 2 mg, p = 0.622).
Non-postoperative DVT were diagnosed in 22/106 (22 %) during running radio(chemo)therapy, 15 % during chemotherapy with temozolomide, 10 % during therapy with nitrosourea, and 6 % during therapy with BEV. The proportion of severe DVT with pulmonary embolism was lower in non-postoperative events (40 % vs. 56 %), without reaching statistical significance (p = 0.133).
Discussion
The present non-interventional observation study provides relevant information on the frequency of the main vascular events in a carefully, prospectively documented, relevant cohort of patients with gliomas. As the participating centres included patients based on the availability of biomaterial from surgery, this analysis provides a clear overview on the natural course of development of vascular complications in gliomas. Limitations of the present data are the only cursory monitoring done on original chart data, and that numbers in the GGN cohort do not necessarily reflect the global incidence of glioma subgroups, as the GGN has certain priority topics in low-grade and anaplastic gliomas. In our cohort, the rate of GB/malignant glioma was lower than in the Central Brain Tumor Registry of the United States (CBTRUS; GGN: 46.3 % vs. CBTRUS: 61.0 %). The rate of grade III and II astrocytoma and oligodendroglioma was, at 39.6 %, much higher in our cohort than in CBTRUS (23.7 %). The rates of PA (GGN: 3.0 %, 
Ischemic strokes
Data pertaining to the frequency of brain infarction in patients with glioma are rare. In a retrospective review of Kreisl et al. [13] , in which glioma (60 %) and other tumor types such as meningioma and central nervous system (CNS) lymphoma were included, minimum ischemic stroke rate was 1.3 % in a population of 5,100 patients. In our study, which is the first focusing only on gliomas, the rate of brain infarction is 70/3,889 patients (1.8 %), and therefore in the same range. Here, there were no differences according to WHO grade. Most ischemic strokes (61 %) occurred postoperatively, and the common cerebrovascular risk factors could be detected less often than in non-postoperative strokes. This observation of a relevant incidence of postoperative ischemic lesions, often explaining an otherwise unexplainable worsening, had been thoroughly followed with DWI studies in the past [29] . Outcome of postoperative versus non-surgery-related ischemias was not different. With anti-angiogenic BEV therapy, more ischemic strokes were documented than without that therapy (6.1 % vs. 0.6 %). This appears surprising, as this was not observed in other studies with glioma [7] (ischemic stroke rate: 1.9 %, no control group) or in side effect monitoring in other extra-cranial tumor entities [18, 26] . On the other hand, intracerebral diffusion-restricted sites in glioma are well known to occur with BEV therapy [9, 19] . The origin and nature of these diffusion-restricted areas are controversially discussed; therapy-associated hypoxic areas in proximity of the tumor [20] or cell-dense tumor areas due to altered tumor growth [17] could be relevant causes. In our MRI analysis, diffusion-restriction was confined to lacunar areas in proximity of tumors, while contrast enhancement in the remaining tumor was decreasing. This allows for both, or an overlap of both explanations.
The high rate of BEV-induced diffusion-restricted sites in glioma patients points to a growth-related specific effect in this tumor entity. These diffusion-restrictions can be associated with neurologic deterioration and should not be seen as harmless side effects, although there might be a relevant number of non-reported asymptomatic cases. In the work of Rieger et al. [19] , 13 (72 %) of 18 analysed patients showed diffusion-restricted sites. The diffusionrestricted areas may even predate contrast-enhancing tumor progression, e.g. in more than 80 % of cases reported by Gupta et al. [9] , and thus might be nothing but another correlate of progressive disease. Eventually, a diffusion restriction next to the tumor under therapy with BEV with neurological worsening may not in most cases be ''classic'' ischemic stroke due to thrombotic or embolic vessel occlusion, but rather a local effect of therapy. It would not be justified to assume an elevated risk of macroangiopathic or embolic stroke under BEV therapy. The exact risk for diffusion-restriction with neurologic worsening should be determined in the context of the ongoing phase III trials (e.g., Avaglio, NCT00943826, [21] ).
Intracranial hemorrhage
The frequency of non-postoperative ICH in glioma varies from 2-25 % in the literature [10, 22, 27] . The postoperative risk for ICH is about 2-5 % [6, 23] .
In our study, ICH was registered in 3.2 % of all patients, and two-thirds of events occurred within 7 days after surgery.
Overall, there was an increase of bleeding rate with WHO grade of the glioma. It remains unclear from our data if this is an effect of a higher number of resections in malignant gliomas. Among anaplastic tumors, a relevant number of non-postoperative ICH occurred in tumors with oligondendroglial or oligoastrocytic differentiation. This might reflect the fact that a tendency for spontaneous bleeding is known in these tumors [14] .
Among non-postoperative ICH, subdural hemorrhages were more frequent. The latter, and the fact that many nonpostoperative ICH start intratumorally without initial major neurologic deficit, might explain the observed better outcome of spontaneous bleedings.
Interestingly, bleeding risk factors were reported in only about one-third of cases in postoperative and non-postoperative ICH. This supports the fact that the majority of nonpostoperative hemorrhage indeed arise ''spontaneously,'' due to fragile tumor blood vessels.
With BEV therapy among 81 patients, only one ICH (according to a rate of 1.2 %) was observed, giving a rate of non-postoperative hematoma similar to that in patients that have never been treated with BEV (1.0 %) and does not support an elevated risk of ICH during BEV therapy, with the limitation of the small number of patients observed in our study.
Comparable results were observed by Friedman et al. [8] (ICH-rate under BEV 2,4 %, with irinotecan 3.8 %, no control group). In BEV-treated patients with primary extracranial tumors, an ICH rate of 3.7 % [12] , and of 1-2 % in patients with intracerebral metastases [2] , was not significantly elevated.
Deep venous thromboembolism
Data pertaining to DVT show an extensively varying probability of 4-30 % to develop DVT during the course of glioma disease [3, 5, 15, 24, 25] . Generally, large studies with some thousand patients show smaller rates than small prospective studies with less than hundred patients. Our rate of 143 events in 2,855 patients (5 %) is in the low range.
A correlation between the rate of DVT and the WHO Grade of glioma has been observed previously [3, 15] . This may not only reflect a higher degree of disability in patients, more intensive concomitant therapies or increasing steroid dose, but may be a specific prothrombotic, paraneoplastic effect of malignant gliomas [11] .
A high rate of DVT has also been found in studies with BEV in malignant glioma (1.6-12.5 %, discussed in [4] ). Larger comparing analyses with BEV-naive control groups only exist for other tumor entities, and showed a moderately increased relative risk for DVT of 1.33 % [16] . Facing the per se very high DVT risk in malignant glioma compared to other tumor entities, our result of only a trend to a higher DVT rate under BEV indicates that the specificity of this risk for BEV treatments in glioblastoma may have been overestimated. Nonetheless, interpretation is weakened by the low number of BEV-treated patients in our cohort.
The comparison of postoperative and non-postoperative DVT did not show significant differences of outcome and other parameters. Patients with non-postoperative DVT were older, which might support the fact that age in itself is a risk factor for DVT [24] .
Conclusions
This study shows current rates and characteristics of vascular complications in patients with glioma. Compared to earlier studies, relatively low rates of ICH and DVT were reported, which might be due to a high proportion of lowgrade gliomas in our patient cohort. Under therapy with BEV, symptomatic, therapy-associated intracerebral diffusion restrictions were seen in a relevant amount of cases.
There was a trend for a higher DVT rate under therapy with BEV. No difference appeared in the frequency of ICH. With respect to our small event numbers in the BEV group, these findings should be controlled in the ongoing phase III studies. advisory board participation from Roche and MSD. He received grant support from Boehringer Ingelheim and MSD.
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